A 65-year-old man underwent an abdominal ultrasound of acute abdominal pain, showing an incidental. Subsequently, a magnetic resonance imaging (MRI) scan of the abdomen revealed additional liver lesions, hyper-intense on T2-weighted images. Needle biopsy of the largest lesion showed a welldifferentiated neuroendocrine tumor (NET) of gastrointestinal origin. The patient underwent a whole-body positron emission tomography-computed tomography (PET/CT) scan using Ga-DOTATATE injection) excision of the tumors from the small bowel, the mesenteric lymph nodes and the liver lesions. Subsequently pathological evaluation of all excised specimens revealed primary grade-I NET in the terminal ileum with metastases to the liver and mesenteric lymph nodes.
Ga-DOTATATE (somatostatin [SST]-analog) for accurate disease staging, which showed approximately 16 tracer-avid liver lesions. The hottest lesion (SUVmax: 52.4) was inferior to the medial segment of the left lobe ( Ga-DOTATATE injection) excision of the tumors from the small bowel, the mesenteric lymph nodes and the liver lesions. Subsequently pathological evaluation of all excised specimens revealed primary grade-I NET in the terminal ileum with metastases to the liver and mesenteric lymph nodes.
Since the majority of NETs overexpress SST receptors, they can be effectively targeted and localized using radiolabeled SST analogs [1, 2] . In the presented case 68Ga-DOTATATE PET/ CT accurately showed the extent of the disease and confidently revealed the location of the primary tumor, demonstrating the utility of PET/CT using 68 Ga-DOTA-conjugated peptides in the accurate management of patients with gastro-enteropancreatic NETs [3] . 
